Core Insights - The article highlights the significant advancements made by the company in the field of cardiovascular intervention, particularly through its products LuX-Valve Plus and JensClip, showcased at the EuroPCR 2025 conference [1][20]. Product Development - LuX-Valve Plus has achieved a 97% success rate in the TRINITY clinical study, which involved high-risk patients with severe tricuspid regurgitation [3][4]. - The device's unique design allows for a wide range of valve sizes (40mm to 70mm), with over 75% of patients using valves ≥55mm, leading to a 95.7% rate of no moderate or severe regurgitation at 30 days post-operation [4][6]. - JensClip has demonstrated a 95% success rate in its one-year follow-up study, with significant improvements in patients' heart function and quality of life [11][13]. Safety and Efficacy - LuX-Valve Plus reported a low 30-day composite event rate of 14.8%, with a cardiovascular mortality rate of just 1.3% [8][9]. - JensClip's one-year all-cause mortality rate was 1.8%, with no incidents of single leaflet grasping or device-related air embolism [14]. Market Positioning - The company is strategically positioned in the global structural heart disease market, which is valued in the hundreds of billions, leveraging its innovative technology and clinical data to build expert consensus [15][20]. - The Chinese medical device industry is experiencing a global expansion, with a reported 5.03% year-on-year increase in medical device exports in Q1 2025 [17]. Global Strategy - The company is executing a multi-regional clinical validation strategy, with ongoing trials in Europe and the U.S., and has established a clinical support network across China and other regions [18][19]. - By cultivating a network of over 90 core operators globally and expanding its presence in approximately 320 key hospitals, the company is enhancing its international medical ecosystem [19]. Financial Performance - The company's stock has surged over 150% year-to-date, indicating market recognition of its differentiated innovative products and strong clinical validation [21].
双产品亮相EuroPCR，健世科技-B（9877.HK）如何用技术优势打开全球心脏介入市场